Lev Pharmaceuticals, Inc.

Lev Pharmaceuticals, Inc., a development stage biopharmaceutical company, develops and commercializes therapeutic products for the treatment of inflammatory diseases. It develops Cinryze (C1 inhibitor), which is a replacement therapy for the acute and prophylactic treatment of hereditary angioedema, also known as C1 inhibitor deficiency characterized by episodes of edema in the extremities, face, abdomen, and airway passages. The company’s products also include C1-INH intended for the treatment of other diseases and disorders, such as acute myocardial infarction or heart attack. It has a strategic alliance with Sanquin Blood Supply Foundation. The company was founded in 2003 and is based in New York, New York.